Related Experiment Video

Updated: Aug 29, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

[Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]

Ping Jia1, Shao-Bo Wu, Qian Xu

  • 1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.

AI Zheng = Aizheng = Chinese Journal of Cancer
|December 25, 2003
PubMed
Abstract

Insights

Antisense oligonucleotide (ASODN) targeting breast cancer resistance protein (BCRP) reduced BCRP mRNA levels in ovarian cancer cells. This reversal of BCRP-mediated drug resistance improved sensitivity to topotecan.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Breast cancer resistance protein (BCRP) overexpression is linked to topotecan resistance in ovarian cancer.
  • BCRP plays a significant role in mediating drug resistance in ovarian cancer cells.

Purpose of the Study:

  • To investigate the reversal effect of BCRP antisense oligonucleotide (ASODN) on topotecan-resistant A2780/TPT ovarian cancer cells.
  • To evaluate the potential of ASODN in overcoming BCRP-mediated drug resistance.

Main Methods:

  • Synthesis of BCRP antisense oligonucleotide (ASODN) and sense oligonucleotide (SODN) as control.
  • Lipofect-2000 (LF) mediated transfection of ASODN/SODN into A2780/TPT cells.
  • Assessment of BCRP mRNA expression (RT-PCR), intracellular rhodamine fluorescence (FCM), and topotecan resistance (MTT assay).

Main Results:

  • ASODN transfection significantly reduced BCRP mRNA levels by 59.42% (P<0.05).
  • Intracellular rhodamine fluorescence intensity increased significantly post-ASODN transfection (from 5.42 to 16.63, P<0.05).
  • Topotecan resistance index decreased from 25 to 5, indicating restored sensitivity in A2780/TPT cells; SODN transfection showed no significant changes.

Conclusions:

  • ASODN transfection demonstrates a capacity to partially reverse BCRP-mediated drug resistance in ovarian cancer cells.
  • Targeting BCRP with ASODN offers a potential strategy to enhance the efficacy of topotecan in ovarian cancer treatment.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Topoisomerases02:02

DNA Topoisomerases

Topoisomerases are enzymes that relax overwound DNA molecules during various cell processes, including DNA replication and transcription. These enzymes regulate positive and negative DNA supercoiling without changing the nucleotide sequence. DNA overwinding in a clockwise direction results in positively supercoiled DNA, whereas underwinding in a counterclockwise direction produces negatively supercoiled DNA.
Types and Mechanism of action
Topoisomerases are divided into two main types.  Type I...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...